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42 The Journal of Thoracic and Cardiobjective: Cardiopulmonary bypass–induced acute liver injury is a life-threatening
omplication thought to be associated with the inflammatory response and the
cute-phase response. Recombinant human growth hormone can modulate the
cute-phase response and inflammatory response. We tested the protective effect of
rowth hormone on cardiopulmonary bypass–induced liver injury in the rat.
ethods: Adult male Sprague–Dawley rats (group G received 2.5 mg/kg recombi-
ant human growth hormone intramuscularly at 8 AM every 24 hours for 3 days and
ust before the initiation of cardiopulmonary bypass; group C served as a control
roup) underwent cardiopulmonary bypass (120 minutes, 120 mL · kg1 · min1,
4°C) and were killed 3 hours after the termination of cardiopulmonary bypass.
esults: Administration of recombinant human growth hormone markedly increased
erum insulin-like growth factor and insulin-like growth factor–binding protein 3
evels compared with those seen in group C. Group G showed significantly lower
erum concentrations of alanine aminotransferase and total bilirubin after cardio-
ulmonary bypass termination. Those receiving recombinant human growth hor-
one demonstrated a significant increase in serum prealbumin and transferrin levels
nd a marked decrease in serum amyloid A and C-reactive protein levels. Recom-
inant human growth hormone significantly decreased serum tumor necrosis factor
and interleukin 1 levels, whereas no changes were found for serum interleukin
and interleukin 10 levels. Recombinant human growth hormone significantly
ncreased total liver protein content and hepatocyte proliferation and decreased
epatocyte apoptosis versus values seen in group C.
onclusions: These results suggest that growth hormone prevents cardiopulmonary
ypass–induced acute liver injury in a rat model through decreases in acute-phase
roteins, proinflammatory cytokines tumor necrosis factor  and interleukin 1, and
epatocyte apoptosis, which is associated with increases in constitutive hepatic
roteins, total liver protein content, and hepatocyte proliferation. This strategy of
retreatment with growth hormone might be a prospective management for pre-
enting acute liver injury when major cardiac surgery with cardiopulmonary bypass
s performed.
ardiopulmonary bypass (CPB) causes severe stress in the cardiac patient,
which can provoke a systemic inflammatory response syndrome.1 The
proinflammatory cytokines are potent inducers of the hepatic acute-phase
rotein (APP) synthesis. These excess inflammatory responses and prolonged acute-
hase responses (APRs) injure various organs and contribute to morbidity and
ortality after cardiac surgery with CPB. The liver is one of the organs vulnerable
o the attack of proinflammatory cytokines. It has long been recognized that early
aundice and liver lesions could appear after CPB surgery.2,3 Recent studies have
xplored whether pharmacologic intervention before reperfusion rather than during
he preservation period could preserve function in vital organs undergoing CPB-
vascular Surgery ● August 2007
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Pnduced inflammatory response and APR.4-9 Building toler-
nce to perioperative damage during the unstressed condi-
ion might result in a more advanced method to assuage
PB-induced inflammatory response and APR, and exploit-
ng a natural defense mechanism called stress response
ight be a potential approach to overcome this problem.
Hepatic APR is an orchestrated cascade of events in
esponse to tissue injury, infection, or inflammatory re-
ponse. Growth hormone (GH) has been shown to enhance
mmune function and to diminish the hypermetabolic re-
ponse after major operations, trauma, sepsis, or thermal
njury.10–15 However, the interaction between the liver and
ecombinant human growth hormone (rhGH) after CPB has
ot been defined. In the current study we tested the in vivo
ffect of GH using a rat CPB model.
aterials and Methods
nimal Care
dult male Sprague–Dawley rats weighing 480  20 g (Animal
upplier Center of Third Military Medical University, Chongqing,
hina) were housed in wire-bottomed cages in a temperature-
ontrolled room with a 12-hour light/dark cycle. Rats were accli-
atized to the environment for 7 days. All animals received
umane care in compliance with the European Convention on
nimal Care. The study was reviewed and approved by the Animal
are and Use Committee of the Third Military Medical University
nd followed the National Research Council’s guidelines.
roup Classification
hirty rats were randomly divided into one of 2 groups according
o the administration of GH before the initiation of CPB. Group G
n 15) intramuscularly received 2.5 mg/kg body weight of rhGH
Serono, Inc) at 8 AM every 24 hours for 3 days and just before the
nitiation of CPB. Group C (n  15) served as a control group and
eceived only saline added in the same way.
All rats underwent 120 minutes of CPB (120 mL · kg1 ·
in1, 34°C, without aortic crossclamping or cardioplegic ar-
est) and were killed 3 hours after the termination of CPB. Ten
ats from each group were used for blood analysis. The remaining
Abbreviations and Acronyms
APP  acute-phase protein
APR  acute-phase response
CPB  cardiopulmonary bypass
GH  growth hormone
GHBP growth hormone–binding protein
IGF  insulin-like growth factor
JAK  Janus kinase
NF  nuclear factor
SAA  serum amyloid A
STAT  signal transducer and activator of
transcription
TNF  tumor necrosis factor0 rats (5 from each group) were used for histologic examinations. a
The Journal of Thoracicurgical Procedures for Rat CPB
ats were anesthetized by means of intraperitoneal administration
f urethane (1 mg/kg) and placed in the supine position. During the
peration, the rat was ventilated with a 14-gauge cannula (fraction
f inspired oxygen, 1.0; frequency, 65 breaths/min; tidal volume,
0 mL/kg body weight) by the use of a rodent ventilator (Rodent
espirator, DH-150). Ventilation was finely adjusted to maintain a
aCO2 of 35 to 40 mm Hg. During CPB, additional urethane was
nflated into the oxygenator to maintain anesthesia. The left fem-
ral artery was cannulated with a 22-gauge heparinized catheter
BD Intima-2 integrated catheter) for continuous pressure mea-
urement and to collect arterial blood gas analysis (blood gas
nalyzer, GEM Premier 3000). The homolateral femoral vein was
annulated with a 20-gauge catheter for liquid replacement. An
8-gauge catheter was inserted into the right jugular vein and
dvanced to the right atrium. This position resulted in good drain-
ge. Subsequently, the left carotid artery was exposed and cannu-
ated with a 22-gauge catheter placed into the aortic arch that
erved as the arterial perfusion line for the extracorporeal circuit.
or anticoagulation, heparin (300 IU/kg) was applied; half of the
ose was administered directly through the left femoral catheter,
nd the other half was administered into the extracorporeal circuit.
The CPB circuit was composed of a roller pump (Polystan
/S), a hollow-fiber oxygenator (surface area, 0.075 m2; especially
ade by Xijing Medical Instruments, Inc), a poikilothermy water
ank (Sarns Machine), a venous reservoir (BD, 20-mL injection
yringes), and sterile tubing with an inner diameter of 4 mm for the
enous line and 1.6 mm for the arterial line. The high siphon level
as 30 cm. The blood was drained from the right atrium through
he right jugular by means of gravity and siphoning and further
ransferred by the roller pump to the hollow-fiber oxygenator and
ack to the rat through the left carotid artery. Priming consisted of
mL of plasma expander, 2 mL of 7% sodium bicarbonate, 2 mL
f mannitol, 4 mL of LR solution, and 1.5 mg of tobramycin.
urthermore, the GH group rats received 10 mg/kg rhGH intra-
uscularly 30 minutes before the establishment of CPB. CPB was
tably performed at 120 mL · kg1 · min1 for 120 minutes, and
erfusate temperature was set at 34°C. At the initiation of CPB, the
ow rate was gradually adjusted to a level that could sustain the
ean arterial pressure near 80 mm Hg; at this point, ventilation
as terminated. During CPB, mean arterial pressure was regulated
t 60 to 80 mm Hg. Heart rate was monitored by means of
lectrocardiography. The hematocrit value was about 25% to 30%.
ith a fraction of inspired oxygen of 100%, 50 mL/min gas flows
ere sufficient to achieve adequate oxygenation and to maintain
aCO2 within 35 to 40 mm Hg. After weaning from the circuit,
eparin was neutralized with 1 mg of protamine for each 100 units
f heparin. The remaining priming solution was infused gradually
fter the termination of CPB. Routinely, termination of CPB was
ided by continuous administration of dobutamine (3 g · kg1 ·
in1). Perioperative hemodynamic data are shown in Table 1.
lood Analysis
rterial blood was sampled at the following 3 times: (1) before the
nitiation of CPB, (2) at the termination of CPB, and (3) 3 hours
fter the termination of CPB.
and Cardiovascular Surgery ● Volume 134, Number 2 343
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CSPeasurements
Serum GH, growth hormone–binding protein, insulin-like
rowth factor, and insulin-like growth factor–binding protein
. Serum human and endogenous rat GH concentrations were
etermined by using a human GH radioimmunoassay (Nichols
nstitute Diagnostics) or a rat GH radioimmunoassay (Biosource
nt) to determine whether the rhGH was biologically active and
aused a response. Serum growth hormone–binding protein
GHBP), insulin-like growth factor (IGF) I, and insulin-like
rowth factor–binding protein (IGFBP) 3 levels were determined
y means of radioimmunoassay (Biosource Int).
Liver function. Blood samples were analyzed for serum con-
entration of albumin, alanine aminotransferase, and total bilirubin
y using an automated biochemical analyzer (Beckman Array
000).
Serum constitutive hepatic proteins and APPs. We measured
erum constitutive hepatic proteins, such as prealbumin and trans-
errin; type I serum APPs, such as C-reactive protein (CRP) and
1-acid glycoprotein; and type II APPs, such as heptoglobin and
1-antitrypsin, by using a Behring nephelometer (Behring). We
etermined type I serum amyloid A (SAA) APP levels by means
f enzyme-linked immunosorbent assay (Genzyme).
Serum cytokines. We determined serum tumor necrosis factor
TNF) , interleukin (IL) 1, IL-6, and IL-10 levels by using a
at-specific enzyme-linked immunosorbent assay (Genzyme).
Liver changes. All rats were killed 3 hours after the termina-
ion of CPB. The entire liver was harvested, weighed, and sec-
ioned. One section (500 mg) was fixed in 4% formalin for histo-
ogic examination, 1 section (500 mg) was used for wet/dry weight
atios, and 1 section (5 g) was snap-frozen in liquid nitrogen for
torage. Hepatic water content was determined by measuring wet/
ry weight ratios. Liver protein concentration was determined by
eans of protein assay (Bio-Rad).
roliferation
iver cell proliferation was determined by means of immunohis-
ochemical staining for proliferative cell nuclear antigen (PCNA).
CNA stains proliferating cells during the G1-M cycle. To deter-
ine proliferating cells, sections were deparaffinized, rehydrated,
nd treated with proteases and HCl to decrease background con-
amination. Nonspecific antigen-binding sites were bound by in-
ubating sections with goat serum, after which the sections were
ncubated with PCNA–horseradish peroxidase conjugate (SC-56) at a
:50 dilution overnight at 4°C and then washed with phosphate-
uffered saline. Finally, the sections were treated with
iaminobenzidine–hydrogen peroxidase for 3 to 6 minutes under
able 1. Perioperative hemodynamic data
ariables Groups
eart rate (beats/min) Group C
Group G
ean arterial pressure (mm Hg) Group C
Group G
ata are expressed as means  standard deviation. CPB, Cardiopulmona
PB; after 3 h, 3 hours after CPB termination; group C, control group; groicroscopic control and counterstained with Mayer’s hematoxylin. (
44 The Journal of Thoracic and Cardiovascular Surgery ● AuguPCNA-positive cells (stained red-brown) were counted on 2
ections from each animal. In each section 2 masked observers
elected 4 different sections for counting PCNA-positive cells.
roliferating cells were identified as those with a brown staining of
he nucleus or cytoplasm. All hepatocytes within the field were
ounted, and proliferation was expressed as a percentage of pro-
iferating cells per 100 hepatocytes. Values for all sections were
veraged to calculate proliferation for the livers of each animal.
poptosis
e used the terminal deoxyuridine nick end-labeling immunohisto-
hemical method (ApopTag, Chemicon) for histologic identification
f apoptotic cells in the liver. Formalin-fixed tissues were processed
nd embedded in paraffin. Sections of 4 m obtained at 40- to
0-m intervals were deparaffinized, rehydrated in graded alcohol,
nd washed in deionized water. Protein was digested with protein-
se K (20 L/mL in phosphate-buffered saline) to decrease back-
round contamination. The sections were then incubated with
reshly prepared terminal deoxyribonucleotidyl transferase en-
yme at 37°C for 2 hours. After the enzyme incubation, the sliders
ere incubated with antidigoxigenin peroxidase at room temper-
ture for 30 minutes. The sections were thoroughly washed, and
iaminobenzidine–hydrogen peroxidase was applied for color de-
elopment for 3 to 6 minutes under microscopic control. Lastly,
he sections were counterstained with Mayer’s hematoxylin and
ounted.
Two sections of each block of tissue were obtained at 40- to
0-m intervals. In each section one masked observer selected 5
elds in 4 different sections (approximately 5500 cells) for count-
ng terminal deoxyuridine nick end-labeling–positive cells. Apo-
totic cells were identified as those with a brown staining of the
ucleus or as apoptotic bodies, which are fragments of apoptotic
ells engulfed by neighboring epithelial cells.
All hepatocytes within the field were counted, and apoptosis
as expresses as a percentage of apoptotic cells per 1000 hepato-
ytes. Values for all sections were averaged to calculate apoptosis
or the liver of each animal.
tatistical Analysis
ll data are presented as means  standard deviation. Compari-
ons between groups were analyzed by means of 2-way repeated-
easures analysis of variance and the unpaired Student t test.
orrelation between data was analyzed with linear regression. All
tatistical analyses were performed with SPSS 10.0 software
Pre-CPB Off CPB After 3 h
360 18 378 15 338  16
355 21 385 19 332  13
82.5 2.1 76.5 6.3 81.7  5.2
78.6 3.3 80.1 5.0 86.3  7.1
ass; pre-CPB, before the initiation of CPB; off CPB, at the termination of
growth hormone administration group.ry bypSPSS, Inc).
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Pesults
s for mean body weight, body temperature, hemoglobin
alue, and PO2, there were no significant differences among
he groups before CPB. There were no technical failures or
perative deaths in the animals used in this study. There
ere no significant differences in hemoglobin level at any
ampling point between the groups, and the degree of CPB-
nduced hemodilution was considered similar in the 2
roups.
erum GH, GHBP, IGF-I, and IGFBP-3 levels
erum human GHBP levels were increased at CPB termi-
ation and 3 hours after CPB termination compared with
hose in group C (P  .05). Endogenous rat GH levels in
roup C were higher than in those in group G (P  .05).
able 2. Changes in serum rat GH, human GHBP, human I
ariables Groups
at GH (g/mL) Group C
Group G
GHBP (g/mL) Group C
Group G
IGF-I (g/mL) Group C
Group G
IGFBP-3 (g/mL) Group C
Group G
ata are expressed as means  standard deviation. CPB, Cardiopulmona
PB; after 3 h, 3 hours after CPB termination; GH, growth hormone; group C
rowth hormone–binding protein; hIGF-I, human insulin-like growth factor I
roup C.
able 3. Changes in liver function and serum constitutive
ariables Groups P
LT (IU/L) Group C 32
Group G 33
B (mol/L) Group C 14
Group G 14
realbumin (mg/L) Group C 288
Group G 291
ransferrin (mg/dL) Group C 71
Group G 70
RP (mg/dL) Group C 4
Group G 4
AA (pg/dL) Group C 321
Group G 318
NF- (pg/dL) Group C 11
Group G 10
L-1 (pg/dL) Group C 18
Group G 17
ata are expressed as means  standard deviation. CPB, Cardiopulmona
PB; after 3 h, 3 hours after CPB termination; ALT, alanine aminotransfe
B, total bilirubin; CRP, C-reactive protein; SAA, serum amyloid A; TNF-,
05 versus group C.
The Journal of Thoracicdministration of rhGH also increased serum levels of both
GF-I and IGFBP-3 at CPB termination and 3 hours after
PB termination compared with those seen in group C (P
05, Table 2).
iver Function
here was significant liver injury at CPB termination and 3
ours after CPB termination in both groups. Administration
f rhGH decreased serum levels of alanine aminotransferase
t CPB termination and 3 hours after CPB termination
ompared with those seen in group C (P  .05). rhGH also
ecreased serum levels of total bilirubin at 3 hours after
PB termination compared with levels in group C (P .01,
able 3). No difference between groups could be shown for
erum albumin levels.
and human IGFBP-3 levels
CPB Off CPB After 3 h
0.7 7.9  0.9 5.8  0.7
1.2 11.9 1.1* 9.1  0.8*
1.1 7.5  0.8 5.1  0.4
0.9 10.1 0.7* 7.9  0.6*
0.7 7.9  0.5 4.5  0.6
1.1 10.9 0.7* 9.8  0.8*
0.7 1.3 0.9 1.1 0.5
1.2 3.5 1.1* 3.9 1.4*
ass; pre-CPB, before the initiation of CPB; off CPB, at the termination of
trol group; group G, growth hormone administration group; hGHBP, human
BP-3, human insulin-like growth factor–binding protein 3. *P  .05 versus
tic protein, APP, and cytokine levels
B Off CPB After 3 h
3.6 130.9 7.5 193.5 11.5
2.9 92.1 6.4* 123.1 9.2†
3.5 29.3 3.7 45.3 4.8
3.1 20.3 5.1* 34.5 4.9†
6.3 215.6  47.6 176.6 45.6
5.6 242.6  45.4* 228.6 46.8*
5.7 55.3 3.9 42.1 2.5
4.9 64.8 6.1* 49.8 3.9*
0.8 12.3 1.7 18.9 2.0
0.6 9.8  2.6* 14.1 1.2*
6.7 502.3  7.9 618.7 11.6
6.1 445.8  8.4* 525.1 12.5*
0.7 60.3 4.9 145.1 8.5
0.4 44.5 3.8* 114.3 5.3*
1.7 77.3 4.2 158.2 9.3
1.4 59.2 3.9* 106.5 10.5*
ass; pre-CPB, before the initiation of CPB; off CPB, at the termination of
group C, control group; group G, growth hormone administration group;
r necrosis factor ; IL-1, interleukin 1. *P  .05 versus group C, †P GF-I,
Pre-
13.6
14.8
11.3
13.4
10.1
11.3
2.1
2.5 
ry byp
, con
; hIGFhepa
re-CP
.6
.5
.8
.1 
.6
.3
.6
.2 
.6
.8 
.3
.6
.2
.9
.6
.1
ry byp
rase;
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CSPerum Constitutive Hepatic Proteins
ll serum constitutive hepatic proteins decreased time de-
endently to less than normal levels after CPB. rhGH sig-
ificantly increased prealbumin and transferrin levels at
PB termination and 3 hours after CPB termination com-
ared with those in group C (P  .05, Table 3).
erum APPs
ll APP levels determined in this study increased time
ependently above normal levels after CPB. Administration
f rhGH decreased serum levels of type I APP SAA and
RP significantly at CPB termination and 3 hours after CPB
ermination compared with those in group C (P  .05, Table
). No difference between groups could be found in serum
evels of type II APPs.
erum Cytokines
ll cytokine levels increased time dependently after CPB.
dministration of rhGH decreased serum levels of TNF-
nd IL-1 significantly at CPB termination and 3 hours after
PB termination compared with those in group C (P  .05,
able 3). No difference between groups could be found in
erum levels of IL-6 and IL-10.
iver Changes
n both groups liver weight increased at 3 hours after CPB
ermination compared with before the initiation of CPB.
his increase in liver weight was associated with an in-
rease in hepatic water content: the wet/dry weight ratio was
ncreased in both groups at 3 hours after CPB termination
ompared with before the initiation of CPB. rhGH treatment
ignificantly decreased the hepatic water assimilation at 3
ours after CPB termination compared with that seen in
roup C (group G vs group C: 0.66  0.01 vs 0.71  0.01;
 .05). rhGH significantly increased hepatic protein con-
entration at 3 hours after CPB termination compared with
hat seen in group C (group G vs group C: 0.98  0.05 vs
.89  0.02 mg/mL; P  .05).
roliferation
epatocyte proliferation increased in both groups at 3 hours
fter CPB termination when compared with physiologic
epatocyte proliferation. Administration of rhGH increased
itogenic activity of hepatocytes at 3 hours after CPB
ermination compared with that seen in group C (P  .05,
igure 1).
poptosis
epatocyte apoptosis increased time dependently after CPB
n both groups. rhGH decreased hepatocyte apoptosis at 3
ours after CPB termination compared with that seen in
roup C (P  .05, Figure 2). T
46 The Journal of Thoracic and Cardiovascular Surgery ● Auguiscussion
PB-induced acute liver injury is a life-threatening compli-
ation after cardiac surgery and is thought to be associated
ith inflammatory responses and APRs. The present study
ses a rat model to ascertain whether GH attenuates CPB-
nduced hepatic APRs aroused by proinflammatory cyto-
ines and thereby protects the liver.
The liver plays a critical role in the APR. The hepatic
PR is initiated by the organism in response to injury, with
he aim of restoring homeostasis.16,17 However, because a
rolonged and uncontrolled increase of this response might
e detrimental, a decrease would improve survival and
linical outcomes.18,19 Mediators of the APR are cytokines,
ncluding the IL-1 family (IL-1/ and TNF-/) and the
L-6 family (eg, IL-6 and IL-11).17 Synthesis and expres-
ion of these cytokines subsequently regulate the synthesis
f APPs.17 The IL-1 family regulates synthesis of type I
PPs, such as SAA, CRP, and 1-acid glycoprotein. The
L-6 family regulates synthesis of type II APPs, such as
eptoglobin, fibrinogen, and 1-antitrypsin. In our experi-
ent, although CPB-induced responses increased proin-
ammatory responses, as indicated by increases in both
NF- and IL-1 levels, these were lower in rats in group
. Decreases in serum TNF- and IL-1 levels were asso-
iated with decreased type I APP SAA, CRP, and 1-acid
lycoprotein levels. These findings are in agreement with
ublished data from a rat study15; GH could modulate the
PR but had no effect on IL-6–like cytokines and type II
PPs on burned rats. The results indicate the possibility of
sing rhGH to protect patients who undergo cardiovascular
urgery with CPB from the detrimental systemic inflamma-
ory response (Figure 3).
The mechanism by which GH modulates the APR are not
ntirely defined; however, it has been demonstrated that GH
inds to its cell-surface receptor and lead to tyrosine phos-
horylation of the CCAAT box/enhancer binding proteins
C/EBP-), the activator protein-1 family of transcription
actors, intracellular tyrosine kinases (Janus kinases
JAKs]), octamer-binding proteins, and signal transducers
nd activators of transcription (STATs).13,15,20 These signal
ranscription factors translocate to the nucleus, where they
an interact with specific DNA sequences to modulate the
ene expression of c-fos/c-jun and nuclear factor (NF) B,
hich regulate the expression of the constitutive hepatic
rotein and APPs.15,20,21 Interestingly, IL-1–like cytokines
egulate constitutive hepatic and APP expression through a
imilar cascade.17 The stimulation of these signals activates
he transcription and translation of type I APP genes. Fur-
hermore, many type I APPs contain NF-B response ele-
ents in their promoter regions but not the type II APPs.17
F-B controls the transcriptional regulation of many
roinflammatory cytokines, including IL-1 and
NF-.17,20 Modulating NF-B activation might cause a
st 2007
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Pecrease in IL-1–like cytokines and type I APPs. Given that
H decreases IL-1–like cytokine levels, it is unknown
hether GH decreases type I APP levels through a direct
ownregulation or through modulation of IL-1–like cyto-
ine expression, which decreases these cellular signals and
onsecutively decreases type I APP levels.15,17,22
In contrast to APPs, constitutive hepatic protein levels
re decreased during the APR because of a reprioritization
f the liver during the APR; that is, the liver reprioritizes its
ynthesis from constitutive hepatic proteins toward APPs to
estore systemic homeostasis.17 However, constitutive he-
atic proteins fulfill important physiologic functions.23
heir downregulation has been described as potentially
armful, and syntheses of these proteins have been used as
redictors for mortality, clinical markers for nutritional sta-
us and severity of stress, and indicators of improved recov-
ry.12,23 In the present study we demonstrated that CPB
ecreased constitutive hepatic proteins. GH administration
ncreased endogenous prealbumin, transferrin, and total pro-
ein concentrations. Similar to the APPs, the mechanism by
Figure 1. A, Rats in group G showed higher mitogenic
animals (*P < .05). Data are presented as means 
(proliferative cell nuclear antigen index) in a represen
hormone 3 hours after cardiopulmonary bypass. Hepat
cytes that underwent mitosis and were considered to
hepatocytes (proliferative cell nuclear antigen index) i
after cardiopulmonary bypass. Compared with panel B,
Magnification 200. Group C, Control group; group G,hich GH increases the concentrations of endogenous con- m
The Journal of Thoracictitutive hepatic proteins is unknown; however, GH might
xert this effect through activation of C/EBP-.24 C/EBP-
s a transactivator of liver-specific genes, such as albumin
nd transferrin, and its messenger RNA concentration de-
reases during trauma and stress and can be considered as a
egative regulated acute-phase gene.17 C/EBP- messenger
NA levels, which are decreased after trauma, were shown
o increase with GH, indicating that a stimulation of the
-isoform might lead consecutively to a stimulation of
onstitutive hepatic proteins, such as prealbumin and
etinol-binding protein.25 We suggest that this increase in
onstitutive hepatic protein levels might be due to a de-
rease in production of APPs, which allows the liver, at
east in part, to redirect its liver protein synthesis.
GH also can exert its effect through stimulation of IGF-I.
GF-I activates JAK/STAT transcription factors during the
PR, as well as C/EBP- receptors, and C/EBP- stimu-
ates IGF-I expression.26 IGF-I might activate the same
ranscription factors as GH, indicating that the IGF-I, JAK/
TAT, and C/EBP- cascade might be a major axis in
ivity of hepatocytes 3 hours after CPB versus control
dard deviation. B, Proliferation rates of hepatocytes
section in rats receiving recombinant human growth
s that stained dark brown were identified as hepato-
ositive. Magnification 200. C, Proliferation rates of
epresentative section in rats receiving saline 3 hours
a few hepatocytes were identified to undergo mitosis.
th hormone administration group.act
stan
tative
ocyte
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only
growodulating the APR that can be activated through GH,
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CSPGF-I, or both substances.27 We demonstrated in this
tudy that serum IGF-I and IGFBP-3 levels were in-
reased with exogenous GH administration, indicating
hat the GH/IGF-I axis might play an important role
uring the APR in CPB.
Preservation of organ homeostasis depends on a balance
etween cell proliferation and cell death.28 CPB has been
hown to induce epithelial cell apoptosis with a concomitant
oss in cellular mass and absorptive surface of the small
owel and to induce apoptosis in myocardial cells with
mpairment in cardiac function.29 Alterations in the balance
etween apoptosis and proliferation might lead to changes
n organ function, integrity, and homeostasis.28,29 Thus it
ight be beneficial after CPB for the organ function either
o increase proliferation or decrease apoptosis. Our study
emonstrated that GH increased hepatocyte proliferation
nd liver protein synthesis, indicating that GH might as-
uage the hypermetabolic response and diminish the nega-
Figure 2. A, Rats in group C showed higher apoptotic a
versus rats in group G. Data are presented as means
(terminal deoxyuridine nick end-labeling index) in a re
growth hormone 3 hours after cardiopulmonary bypas
apoptosis (stained dark brown) and were considered
hepatocytes (terminal deoxyuridine nick end-labeli
saline 3 hours after cardiopulmonary bypass. Comp
undergo apoptosis. Magnification 200. Group C, C
group.ive nitrogen balance. Thus pretreatment with GH might be t
48 The Journal of Thoracic and Cardiovascular Surgery ● Augueneficial for liver function and systemic homeostasis for
atients undergoing CPB. We also showed that CPB in-
uced hepatocyte apoptosis, which could be decreased by
H administration.
The mechanisms by which CPB induces hepatocyte ap-
ptosis are not defined. Studies have suggested that in
eneral hypoperfusion, ischemia and reperfusion, and in-
reased levels of proinflammatory cytokine, such as IL-
/, TNF-, and IL-6, are associated to promote apopto-
is.29,30 In our experiment we did not examine the effect of
H on hepatic blood flow; however, we showed that GH
ecreased IL-1 and TNF- levels. This attenuation might
e the reason why GH decreases hepatocyte apoptosis.
In conclusion, GH prevents acute liver injury induced by
PB in rats through modulation of APR by affecting IGF-I
nd IL-1–like cytokine expression, which leads to decreased
ype I APP levels, IL-1–like cytokine synthesis, and hepa-
ocyte apoptosis and increased constitutive hepatic proteins,
y of hepatocytes 3 hours after cardiopulmonary bypass
tandard deviation. B, Apoptotic rates of hepatocytes
entative section in rats receiving recombinant human
ly a few hepatocytes were identified that underwent
e positive. Magnification 200. C, Apoptotic rates of
dex) in a representative section in rats receiving
with panel B, more hepatocytes were identified to
ol group; group G, growth hormone administrationctivit
 s
pres
s. On
to b
ng in
ared
ontrotal liver protein content, and hepatocyte proliferation. This
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Ptrategy of pretreatment with GH might be a prophylactic
ption to prevent liver injury when major cardiac surgery
ith CPB is performed.10,11,14
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